India, Oct. 5 -- Alterity Therapeutics Ltd. (ATHE) reported new analyses from its Phase 2 ATH434-201 trial showing that ATH434 50 mg slowed functional decline in patients with multiple system atrophy (MSA).
After adjusting for baseline cerebrospinal fluid neurofilament light chain (CSF NfL), ATH434 50 mg produced a 4.64-point difference versus placebo on the 11-item UMSARS Part I at Week 52 (p=0.032), representing approximately 52% slowing of functional decline.
CSF NfL is an established biomarker associated with disease progression in MSA. The analysis found that every 1,000 pg/mL increase in baseline CSF NfL was associated with approximately 0.9 points of additional UMSARS Part I worsening at Week 52.
The 75 mg dose also showed a numer...